Don’t invest unless you’re prepared to lose all your money invested. Investments in our companies are high-risk investments. You could lose all the money you invest and are unlikely to be protected if something goes wrong. Please take 2 mins to learn more by clicking this link and viewing our summary of key risks.

Semarion PR

Portfolio company Semarion announces Early Adopter Programme

Semarion announces Early Adopter Programme for SemaCyte Microcarriers for Cell Assays

Semarion Ltd, a University of Cambridge spin-out combining materials engineering and cell biology to tackle unmet drug screening needs, today announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform. The platform overcomes current limitations associated with adherent cell culture and assaying workflows by enabling small colonies of cells to be moved and frozen in their adherent state, increasing the volume of data collected per experiment and reducing the resource demands of in vitro drug discovery.

Researchers are now invited to register their interest to be included in the Company’s Early Adopter Programme, which will allow access to the SemaCyte Microcarrier Platform and provide first-hand experience of how the technology can improve drug discovery workflows. Semarion is also offering demonstrations via a webinar, and a demonstration day at its laboratories in Cambridge. To apply to be included in the programme, please visit:

Find out more on Semarion's website.